These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

573 related articles for article (PubMed ID: 26027660)

  • 21. The comparison between dual inhibition of mTOR with MAPK and PI3K signaling pathways in KRAS mutant NSCLC cell lines.
    Dogan Turacli I; Ozkan AC; Ekmekci A
    Tumour Biol; 2015 Dec; 36(12):9339-45. PubMed ID: 26108998
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combined targeting of AKT and mTOR using MK-2206 and RAD001 is synergistic in the treatment of cholangiocarcinoma.
    Ewald F; Grabinski N; Grottke A; Windhorst S; Nörz D; Carstensen L; Staufer K; Hofmann BT; Diehl F; David K; Schumacher U; Nashan B; Jücker M
    Int J Cancer; 2013 Nov; 133(9):2065-76. PubMed ID: 23588885
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synergistic effects of erlotinib and everolimus on bronchial carcinoids and large-cell neuroendocrine carcinomas with activated EGFR/AKT/mTOR pathway.
    Bago-Horvath Z; Sieghart W; Grusch M; Lackner A; Hayden H; Pirker C; Komina O; Węsierska-Gądek J; Haitel A; Filipits M; Berger W; Schmid K
    Neuroendocrinology; 2012; 96(3):228-37. PubMed ID: 22378048
    [TBL] [Abstract][Full Text] [Related]  

  • 24. mTORC1 inhibitor RAD001 (everolimus) enhances non-small cell lung cancer cell radiosensitivity in vitro via suppressing epithelial-mesenchymal transition.
    Chen Y; Li WW; Peng P; Zhao WH; Tian YJ; Huang Y; Xia S; Chen Y
    Acta Pharmacol Sin; 2019 Aug; 40(8):1085-1094. PubMed ID: 30796356
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The combination of multiple receptor tyrosine kinase inhibitor and mammalian target of rapamycin inhibitor overcomes erlotinib resistance in lung cancer cell lines through c-Met inhibition.
    Nakachi I; Naoki K; Soejima K; Kawada I; Watanabe H; Yasuda H; Nakayama S; Yoda S; Satomi R; Ikemura S; Terai H; Sato T; Ishizaka A
    Mol Cancer Res; 2010 Aug; 8(8):1142-51. PubMed ID: 20647329
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hydroxysafflor yellow A inhibited lipopolysaccharide-induced non-small cell lung cancer cell proliferation, migration, and invasion by suppressing the PI3K/AKT/mTOR and ERK/MAPK signaling pathways.
    Jiang M; Zhou LY; Xu N; An Q
    Thorac Cancer; 2019 Jun; 10(6):1319-1333. PubMed ID: 31055884
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MKP1 repression is required for the chemosensitizing effects of NF-kappaB and PI3K inhibitors to cisplatin in non-small cell lung cancer.
    Cortes-Sempere M; Chattopadhyay S; Rovira A; Rodriguez-Fanjul V; Belda-Iniesta C; Tapia M; Cejas P; Machado-Pinilla R; Manguan-García C; Sánchez-Pérez I; Nistal M; Moratilla C; de Castro-Carpeño J; Gonzalez-Barón M; Albanell J; Perona R
    Cancer Lett; 2009 Dec; 286(2):206-16. PubMed ID: 19553005
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting PI3K/AKT/mTOR pathway in non small cell lung cancer.
    Fumarola C; Bonelli MA; Petronini PG; Alfieri RR
    Biochem Pharmacol; 2014 Aug; 90(3):197-207. PubMed ID: 24863259
    [TBL] [Abstract][Full Text] [Related]  

  • 29. LKB1/KRAS mutant lung cancers constitute a genetic subset of NSCLC with increased sensitivity to MAPK and mTOR signalling inhibition.
    Mahoney CL; Choudhury B; Davies H; Edkins S; Greenman C; Haaften Gv; Mironenko T; Santarius T; Stevens C; Stratton MR; Futreal PA
    Br J Cancer; 2009 Jan; 100(2):370-5. PubMed ID: 19165201
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Auranofin-mediated inhibition of PI3K/AKT/mTOR axis and anticancer activity in non-small cell lung cancer cells.
    Li H; Hu J; Wu S; Wang L; Cao X; Zhang X; Dai B; Cao M; Shao R; Zhang R; Majidi M; Ji L; Heymach JV; Wang M; Pan S; Minna J; Mehran RJ; Swisher SG; Roth JA; Fang B
    Oncotarget; 2016 Jan; 7(3):3548-58. PubMed ID: 26657290
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Everolimus prolonged survival in transgenic mice with EGFR-driven lung tumors.
    Yasugi M; Takigawa N; Ochi N; Ohashi K; Harada D; Ninomiya T; Murakami T; Honda Y; Ichihara E; Tanimoto M; Kiura K
    Exp Cell Res; 2014 Aug; 326(2):201-9. PubMed ID: 24768699
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Everolimus exhibits efficacy as a radiosensitizer in a model of non-small cell lung cancer.
    Mauceri HJ; Sutton HG; Darga TE; Kocherginsky M; Kochanski J; Weichselbaum RR; Vokes EE
    Oncol Rep; 2012 May; 27(5):1625-9. PubMed ID: 22294050
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term acquired everolimus resistance in pancreatic neuroendocrine tumours can be overcome with novel PI3K-AKT-mTOR inhibitors.
    Vandamme T; Beyens M; de Beeck KO; Dogan F; van Koetsveld PM; Pauwels P; Mortier G; Vangestel C; de Herder W; Van Camp G; Peeters M; Hofland LJ
    Br J Cancer; 2016 Mar; 114(6):650-8. PubMed ID: 26978006
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combination of PI3K/mTOR inhibitors: antitumor activity and molecular correlates.
    Mazzoletti M; Bortolin F; Brunelli L; Pastorelli R; Di Giandomenico S; Erba E; Ubezio P; Broggini M
    Cancer Res; 2011 Jul; 71(13):4573-84. PubMed ID: 21602434
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Plumbagin induces apoptotic and autophagic cell death through inhibition of the PI3K/Akt/mTOR pathway in human non-small cell lung cancer cells.
    Li YC; He SM; He ZX; Li M; Yang Y; Pang JX; Zhang X; Chow K; Zhou Q; Duan W; Zhou ZW; Yang T; Huang GH; Liu A; Qiu JX; Liu JP; Zhou SF
    Cancer Lett; 2014 Mar; 344(2):239-59. PubMed ID: 24280585
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Marsdenia tenacissima extract restored gefitinib sensitivity in resistant non-small cell lung cancer cells.
    Han SY; Zhao MB; Zhuang GB; Li PP
    Lung Cancer; 2012 Jan; 75(1):30-7. PubMed ID: 21757251
    [TBL] [Abstract][Full Text] [Related]  

  • 37. TAZ inhibition restores sensitivity of cisplatin via AKT/mTOR signaling in lung adenocarcinoma.
    Xu W; Wei Y; Li Y; Yin Y; Yuan W; Yang Y; Zhao W; Wu J
    Oncol Rep; 2017 Sep; 38(3):1815-1821. PubMed ID: 28737828
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dependence on phosphoinositide 3-kinase and RAS-RAF pathways drive the activity of RAF265, a novel RAF/VEGFR2 inhibitor, and RAD001 (Everolimus) in combination.
    Mordant P; Loriot Y; Leteur C; Calderaro J; Bourhis J; Wislez M; Soria JC; Deutsch E
    Mol Cancer Ther; 2010 Feb; 9(2):358-68. PubMed ID: 20124452
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rapamycin Enhances the Anti-Cancer Effect of Dasatinib by Suppressing Src/PI3K/mTOR Pathway in NSCLC Cells.
    Chen B; Xu X; Luo J; Wang H; Zhou S
    PLoS One; 2015; 10(6):e0129663. PubMed ID: 26061184
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Paradigm of kinase-driven pathway downstream of epidermal growth factor receptor/Akt in human lung carcinomas.
    Dobashi Y; Suzuki S; Kimura M; Matsubara H; Tsubochi H; Imoto I; Ooi A
    Hum Pathol; 2011 Feb; 42(2):214-26. PubMed ID: 21040950
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.